Cancer-induced expansion and activation of CD11b+ Gr-1+ cells predispose mice to adenoviral-triggered anaphylactoid-type reactions

Molecular Therapy

Volumn 17, Issue 3, 2009, Pages 508-515

  Pande, Kalyan ^a   Ueda, Roanna ^a   Machemer, Todd ^a   Sathe, Manjiri ^a   Tsai, Van ^a   Brin, Elena ^a   Delano, Matthew J ^b   Van Rooijen, Nico ^c   McClanahan, Terrill K ^a   Talmadge, James E ^d   Moldawer, Lyle L ^b   Phillips, Joseph H ^a   LaFace, Drake M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CLODRONIC ACID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NITRIC OXIDE SYNTHASE INHIBITOR;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CARDIOVASCULAR RESPONSE; CD11+GR-1 MYELOID CELL; CELL ACTIVATION; CELL COUNT; CELL EXPANSION; CELL SUBPOPULATION; CELL TRANSFER; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENE EXPRESSION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PASSIVE TRANSPORT; PHAGOCYTE; SINGLE DRUG DOSE; SPLEEN CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANAPHYLAXIS; ANIMALS; ANTIGENS, CD11B; CARDIOVASCULAR SYSTEM; CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE SUSCEPTIBILITY; FEMALE; GENE THERAPY; HEART RATE; HUMANS; LEUKOTRIENE ANTAGONISTS; LIPOSOMES; MICE; MYELOID CELLS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NITRIC OXIDE SYNTHASE; PHAGOCYTES; RECEPTORS, CHEMOKINE; RECEPTORS, LEUKOTRIENE;

ADENOVIRIDAE; ANIMALIA; MUS;

EID: 61649095862     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.280     Document Type: Article

References (33)

1. Sinha, P, Clements, VK, Miller, S and Ostrand-Rosenberg, S (2005). Tumor immunity: A balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 54: 1137-1142.
2. Terabe, M, Matsui, S, Park, JM, Mamura, M, Noben-Trauth, N, Donaldson, DD et al. (2003). Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198: 1741-1752.
3. + T cells. J Clin Invest 116: 2777-2790.
4. Kusmartsev, S and Gabrilovich, DI (2002). Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 51: 293-298.
5. Yang, L, DeBusk, LM, Fukuda, K, Fingleton, B, Green-Jarvis, B, Shyr, Y et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421.
6. Shojaei, F, Wu, X, Zhong, C, Yu, L, Liang, XH, Yao, J et al. (2007). Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450: 825-831.
7. + myeloid cells that promote metastasis. Cancer Cell 13: 23-35.
8. Strait, RT, Morris, SC, Yang, M, Qu, XW and Finkelman, FD (2002). Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol 109: 658-668.
9. Finkelman, FD (2007). Anaphylaxis: Lessons from mouse models. J Allergy Clin Immunol 120: 506-515; quiz 516-507.
10. Scherer, K, Studer, W, Figueiredo, V and Bircher, AJ (2006). Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: Case report and review of the nomenclature of vital blue dyes. Ann Allergy Asthma Immunol 96: 497-500.
11. Castells, M (2006). Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol 6: 271-277.
12. Markman, M, Kennedy, A, Webster, K, Elson, P, Peterson, G, Kulp, B et al. (1999). Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17: 1141.
13. Wilke, LG, McCall, LM, Posther, KE, Whitworth, PW, Reintgen, DS, Leitch, AM et al. (2006). Surgical complications associated with sentinel lymph node biopsy: Results from a prospective international cooperative group trial. Ann Surg Oncol 13: 491-500.
14. Albo, D, Wayne, JD, Hunt, KK, Rahlfs, TF, Singletary, SE, Ames, FC et al. (2001). Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg 182: 393-398.
15. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. (2005). The diagnosis and management of anaphylaxis: An updated practice parameter. J Allergy Clin Immunol 115: S483-S523.
16. Machemer, T, Engler, H, Tsai, V, Lee, S, Cannon-Carlson, S, Voloch, M et al. (2005). Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses. Mol Ther 12 254-263.
17. Schiedner, G, Bloch, W, Hertel, S, Johnston, M, Molojavyi, A, Dries, V et al. (2003). A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 14: 1631-1641.
18. Morrissey, RE, Horvath, C, Snyder, EA, Patrick, J, Collins, N, Evans, E et al. (2002). Porcine toxicology studies of SCH 58500, an adenoviral vector for the p53 gene. Toxicol Sci 65: 256-265.
19. Van Rooijen, N and Sanders, A (1994). Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93.
20. Aslakson, CJ and Miller, FR (1992). Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405.
21. Serafini, P, Borrello, I and Bronte, V (2006). Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53-65.
22. Gould, HJ, Sutton, BJ, Beavil, AJ, Beavil, RL, McCloskey, N, Coker, HA et al. (2003). The biology of IGE and the basis of allergic disease. Annu Rev Immunol 21: 579-628.
23. Lieber, A, He, CY, Meuse, L, Schowalter, D, Kirillova, I, Winther, B et al. (1997). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71: 8798-8807.
24. Smith, JS, Tian, J, Lozier, JN and Byrnes, AP (2004). Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Mol Ther 9: 932-941.
25. Elgert, KD, Alleva, DG and Mullins, DW (1998). Tumor-induced immune dysfunction: The macrophage connection. J Leukoc Biol 64: 275-290.
26. Danna, EA, Sinha, P, Gilbert, M, Clements, VK, Pulaski, BA and Ostrand- Rosenberg, S (2004). Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64: 2205-2211.
27. Maindrault-Goebel, F, Andre, T, Tournigand, C, Louvet, C, Perez-Staub, N, Zeghib, N et al. (2005). Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients. Eur J Cancer 41: 2262-2267.
28. Lenz, G, Hacker, UT, Kern, W, Schalhorn, A and Hiddemann, W (2003). Adverse reactions to oxaliplatin: A retrospective study of 25 patients treated in one institution. Anticancer Drugs 14: 731-733.
29. Zea, AH, Rodriguez, PC, Atkins, MB, Hernandez, C, Signoretti, S, Zabaleta, J et al. (2005). Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res 65: 3044-3048.
30. Almand, B, Clark, JI, Nikitina, E, van Beynen, J, English, NR, Knight, SC et al. (2001). Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 166: 678-689.
31. Reid, T, Warren, R and Kirn, D (2002). Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 9: 979-986.
32. Huyghe, BG, Liu, X, Sutjipto, S, Sugarman, BJ, Horn, MT, Shepard, HM et al. (1995). Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 6 1403-1416.
33. Fehniger, TA, Shah, MH, Turner, MJ, VanDeusen, JB, Whitman, SP, Cooper, MA et al. (1999). Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response. J Immunol 162: 4511-4520.